Next Phase Newsletter

A corporate venture arm of a holding company seeks to foster innovation across the group by investing in and partnering with strategic startups. In principle, the corporate venture capital arm is open to global opportunities and is geography and stage agnostic, but has specific preferences depending on the technology sector.

Healthcare/Medical is one of the major focus areas of the group. The firm is interested in therapeutics solutions such as solutions beyond the pill (digital therapeutics) and around the pill (delivery systems etc). Therapeutics areas of interest are CNS, Autoimmune diseases, metabolic diseases, regenerative medicine, Aging related solutions and Vaccines. Corporate venture capital arm is also interested in diagnostics solutions based on genomics, metagenomics, metabolomics, healthcare ICT (biosensors etc), and medical big data.  Furthermore, medical devices for wound care, bone cement and hospital related infection treatment is also is an area of interest and is open to all classes of medical devices including 510k and PMA.

The corporate venture capital arm of MCG has a close, collaborative relationship with other branches within the group and can also present opportunities to the pharma branch, CRO, CDMO branches as appropriate.

The firm is a flexible investor. For medical device & digital therapeutics opportunities, the group does prefer technologies with strong promise in the US market. The venture group has a close relationship with all other business operations within the holding company and can actively support companies by leveraging these relationships.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with multiple offices in the US manages assets under management of $1.6 billion. Since inception, the firm has raised five investment funds. The firm typically makes equity investments in U.S.-based companies, with portfolio companies located on both coasts and throughout the central part of the country. The firm will consider investing at all stages, with a focus on seed and early-stage investments, including founding companies. Investment size is up to $20 million throughout a portfolio company’s path to liquidity.

The firm is currently looking for new investment opportunities in the life science space, with a specific focus on biopharmaceuticals and therapeutic medical devices. The firm has invested in biopharmaceutical companies focused on developing drugs to treat enteral feeding intolerance and disorders that are driven by CD47-mediated signaling pathways, including leukemia, lymphoma, solid tumors, and pulmonary hypertension. In addition, the firm has invested in a medical device developing a minimally-invasive, catheter-based device to re-create valves in deep leg veins. The firm does not look at diagnostics, though may be interested in technology with real-time feedback for procedures.

The firm focuses on identifying and shaping early-stage life science companies in the series A/B rounds to create significant shareholder value. Because of its extensive operating expertise, the firm is able to help entrepreneurs achieve near-term objectives that position their companies for exit.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The venture fund and venture builder invests in multiple healthcare sectors including therapeutics and synthetic biology, life science tools, IVD, medical devices, digital health and microbiome. The firm invests in pre-seed/seed stage companies with some proof of concept, looking to be the first institutional money in. The firm will invest globally, and looks to invest between $400k-1M. As an igniter, the firm takes a very active role in company formation, development and executive management.

The firm is interested in therapeutics, life science tools, medical devices, synthetic biology, and microbiome related technologies. Within these areas, anything relevant will be considered, including digital health and in vitro diagnostics. The firm is agnostic to indication.

The firm only invests in the first institutional capital round. The firm can invest, or act as a co-founder, depending on the needs of the company/founding team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The investor is a Venture Capital firm based in San Francisco California. The firm is interested in making equity investments into early stage companies with investments ranging from $1M to $15 million per company, depending on the companies needs and stage of development. The firm is currently seeking investment opportunities throughout the United States.

The firm is looking for companies operating in Precision medicine, MedTech and medicine at the edge, AI-enabled services such as drug discovery and clinical trial support, and synthetic biology with a software component. The firm is entirely opportunistic in terms of indication and will consider companies at all stages of development.

The firm is looking for privately held companies with strong management teams. The firm is able to provide entrepreneurs with a 200-person advisory network and bring deep operational expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The venture studio located in New York City. In addition to its core venture creation function, the group in early-stage digital health companies looking to enter the US market for which its platform can offer catalytic growth. In addition to providing capital, the firm assists companies with regulatory approval and commercialization in the US, through their unique company creation partnership with a large health system.

The firm invests across the spectrum of digital health, with a particular focus on companies developing AI-based technologies, virtual care and other health-related technologies.

The firm generally seeks to work hand-in-hand with management to drive value creation and assist portfolio companies with US market entry. They work with pre-revenue companies, as well as with those that are more advanced internationally and looking to enter the US market. The firm considers both minority investments and acquisitions.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The seed-stage VC fund headquartered on the West Coast and founded in 2020. The firm focuses exclusively on pediatrics, and will invest in all sectors. The firm invests out of an evergreen fund, and looks to invest $500k-1M in US-based companies that have raised some non-dilutive capital. Many of the firm’s portfolio companies come from The firm’s connections with incubators and universities. For stage of development, the firm prefers for device companies to have hit initial regulatory milestones, and for diagnostics and digital health companies to have had a pilot study. For therapeutics, the firm has a strong interest in repurposed drugs.

While the firm is agnostic to sector and subsector, they will only invest in companies whose primary indication is related to pediatrics, including orphan indications.

The firm is an active investor, and likes to play a role in helping the company advance. They tend to co-invest, and generally do not require a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A leading European Venture Capital firm investing in early-and growth stage life science companies is focused on investing in the most promising life science companies in the fields of biotechnology, therapeutics, medical technology, diagnostics and digital health. With funds totaling EUR 1.0 billion, the firm has been actively supporting world class private companies translating true innovation into successful businesses with exceptional growth. To date, the firm has invested in over 50 innovative life science companies. Initial ticket size ranges between EUR 5-10 million and up to EUR 20 million over the life of the investment.

The firm invest mainly in Europe and selectively in US across five broad areas:  Therapeutics, Medtech, Diagnostics, Digital Health and Biotechnology and R&D tools. Regarding therapeutics, the firm focuses on early-stage companies with preclinical proof of concept data or about to enter the clinic, with a preference for companies developing highly innovative technology platforms, or with early clinical data. In the other fields, the firm prefers companies with product candidates (with strong IP protection) approaching regulatory approval or companies who have already launched a first product and have some early market traction in the single million digit range.

The firm typically requests a board seat and looks for a strong and experienced management team while supporting highly talented entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.